Upstream Bio (UPB) Receivables (2023 - 2026)

Upstream Bio's Receivables history runs 4 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Receivables rose 50.0% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 50.0% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 96.69% from the prior year.
• Receivables advanced to $2.6 million in Q1 2026 per UPB's latest filing, from $2.3 million in the prior quarter.
• Across five years, Receivables topped out at $2.6 million in Q2 2025 and bottomed at $236000.0 in Q4 2023.
• The 4-year median for Receivables is $1.7 million (2025), against an average of $1.6 million.
• Across the five-year window, Receivables surged 400.0% in 2024 and soared 50.0% in 2026, its largest moves.
• Year by year, Receivables stood at $236000.0 in 2023, then jumped by 400.0% to $1.2 million in 2024, then soared by 96.69% to $2.3 million in 2025, then advanced by 12.32% to $2.6 million in 2026.
• Per Business Quant, the three latest UPB Receivables figures stand at $2.6 million (Q1 2026), $2.3 million (Q4 2025), and $2.3 million (Q3 2025).